Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that quality of life, overall survival, and progression-free survival are the most important factors for postmenopausal patients with advanced breast cancer when considering treatment options.

This study reported an almost doubling of advanced breast cancer incidence in women under 40 over three decades, but its significance remains uncertain and requires further confirmation.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.